Where Waldenström macroglobulinemia treatment is heading
Waldenström macroglobulinemia · Updated Nov 14, 2026
Waldenström macroglobulinemia (WM) is a slow-growing blood cancer in which abnormal B cells fill the bone marrow and make large amounts of an antibody called IgM, which can thicken the blood and damage nerves. About 1,000 to 1,500 Americans are diagnosed each year, mostly over 65. Most cases carry a MYD88 mutation, which makes WM very sensitive to BTK inhibitor pills. Those pills are taken indefinitely, so trials now test time-limited combinations, BCL2 inhibitors, BTK degraders and radioactive drugs.
- 79studies open or running
- 3phase 3 trials
- 234papers published this year
-
Now
Nov 2026
Better-tolerated BTK inhibitorsHappened 36.3% deep responses
Zanubrutinib gave deep responses in 36.3% vs 25.3% with ibrutinib, with less atrial fibrillation.
36.3%: very good partial or complete response with zanubrutinib, vs 25.3% with ibrutinib.
Long-lasting controlHappened 94.6% response rate
Acalabrutinib responses held for more than 5 years in many patients.
94.6%: response rate in relapsed disease.
An option after BTK inhibitorsHappened 82.5% response rate
Pirtobrutinib worked in 81.0% of people who had already taken a covalent BTK inhibitor.
82.5%: response rate.
-
6 months
by May 2027
BCL2 inhibitor combinationsPossible
BeOne's sonrotoclax plus zanubrutinib trial (114 people) finishes September 2026.
-
12 months
by Nov 2027
A BTK degraderPossible
Tacabrutideg, which destroys the BTK protein instead of blocking it, is in a large study (689 people) due March 2027.
Testing for CXCR4Possible 72% 4-year progression-free
CXCR4 mutation status increasingly guides whether to add rituximab.
72%: 4-year progression-free with rituximab in CXCR4-mutated WM, vs 43%.
-
3 years
by late 2029
Time-limited treatmentPossible
ECWM-2 and an NCI trial test venetoclax with rituximab (both due March 2028); a French trial tests fixed-duration zanubrutinib plus sonrotoclax (due December 2028).
-
5 years
by late 2031
Pills vs chemotherapy, head to headPossible
RAINBOW (148 people) compares ibrutinib-rituximab with chemoimmunotherapy; due March 2030.
A radioactive drugLong shot
Cellectar's iopofosine I-131 phase 3 (219 people) is due January 2032.
The research paths
BTK inhibitors and degraders
82.5% response rateDetails and 2 trialsHide
More selective BTK inhibitors, non-covalent pills and BTK degraders.
WatchTacabrutideg; nemtabrutinib.
Time-limited combinations
72% 4-year progression-freeDetails and 5 trialsHide
BCL2 inhibitors and antibodies added so treatment can stop.
WatchECWM-2; sonrotoclax trials.
- Sonrotoclax with zanubrutinibBeOne Medicines · 114 people · fully enrolled Sep 2026
- Fixed-duration zanubrutinib plus sonrotoclaxFrench Innovative Leukemia Organization · 102 people · not yet open Dec 2028
- Venetoclax-rituximab vs DRC (ECWM-2)Christian Buske · 80 people · enrolling Mar 2028
- Venetoclax-rituximab vs usual treatmentNational Cancer Institute · 92 people · enrolling Mar 2028
- Carfilzomib plus ibrutinib vs ibrutinibChristian Buske · 99 people · fully enrolled May 2028
Head-to-head and radioactive drugs
Details and 2 trialsHide
Comparing pills with chemotherapy, and testing a targeted radioactive drug.
WatchRAINBOW; iopofosine.
Borrowed from other cancers
From Chronic lymphocytic leukemia
Venetoclax and sonrotoclax
Phase 2
BCL2 inhibitors that allow fixed-length treatment in CLL.
From CLL and mantle cell lymphoma
Pirtobrutinib
Phase 1/2
A non-covalent BTK inhibitor approved for CLL and mantle cell lymphoma.
From Multiple myeloma
Carfilzomib
Phase 2
A proteasome inhibitor added to ibrutinib.
Open to join now
-
Untreated WM
Ibrutinib-rituximab vs DRC
Locations and eligibility → -
WM
Venetoclax-rituximab
Locations and eligibility → -
Relapsed B-cell cancers including WM
Tacabrutideg
Locations and eligibility → -
Untreated WM
Venetoclax-rituximab vs DRC
Locations and eligibility →
See every recruiting WM trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Acalabrutinib responses last beyond 5 years
ACE-WM-001, Blood Advances.
Pirtobrutinib works after other BTK inhibitors
BRUIN, Lancet Haematology.
Standard treatment today
- No symptoms (smoldering)Watchful waiting with regular blood tests.
- First treatmentA BTK inhibitor (zanubrutinib, ibrutinib, acalabrutinib) or bendamustine-rituximab; DRC for some.
- RelapsedSwitch class: chemoimmunotherapy, pirtobrutinib, venetoclax or a clinical trial.
- Very high IgM (hyperviscosity)Urgent plasma exchange before treatment.
How to read this page, and sourcesHow to read this page, and sources
- Many people with WM need no treatment for years; treatment usually starts only when symptoms appear.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See WM trials recruiting now →